Analysis of Nasopharyngeal Microbiota in Patients With Respiratory Infections

NCT06556420 | Not Yet Recruiting

• 1 other identifier: 6603
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Respiratory tract infections represent the most frequent infectious pathology in community environments and when of bacterial origin, imply a morbid state generally supported by a pathogenic bacterial species predominant on the commensal flora of the airways. Among the most frequent bacterial infections of the upper respiratory tract in pediatric age we find acute bacterial pharyngitis or pharyngotonsillitis caused by Streptococcus pyogenes (β-hemolytic group A), for which antimicrobial therapy is clearly indicated, and which manifests itself with an onset sudden fever. It should also be remembered that some forms of pharyngitis are caused by Chlamydia pneumoniae, Mycoplasma pneumoniae, Bordetella pertussis and Legionella, commonly responsible for lower respiratory tract infections but recently also associated with upper respiratory tract infections. In childhood, a viral or bacterial infection of the upper respiratory tract (in particular pharyngitis, laryngitis) can easily lead to an infection of the lower respiratory tract (pneumonia). In fact, the inflammatory process triggered by a previous infection, generally viral, determines an impairment of mucociliary clearance which facilitates the proliferation not only of pathogenic bacteria but also of the commensal bacterial flora, normally non-pathogenic. An altered local microbial flora can, therefore, contribute to the pathogenesis of new infections or itself be responsible for invasive infections. The microbiota of the upper airways may therefore be a further factor influencing the susceptibility, frequency and severity of acute respiratory diseases. The oropharyngeal microbiota is in fact made up of numerous bacterial species which, by colonizing this anatomical tract, interact with the mucosa of the pharynx and therefore with the immune system, contributing to the homeostasis of the upper respiratory tract and consequently also preserving the integrity of the lower respiratory tract. As observed for other anatomical sites, the composition of the oropharyngeal microbiota is conditioned by external events, among which we find the use of antibiotics or oral disinfectant drugs which can favor the development of pathogenic microorganisms. Characterizing the oropharyngeal microbiota in a state of acute and/or chronic respiratory infection could increase knowledge on the microbiological signature associated with such infections and ineffective antibiotic treatments. Greater knowledge of it, also with future corrective purposes, as has now been demonstrated for other body areas, could be of great help in reducing the risk of acute recurrent disease and/or chronic consequences.

Conditions

Respiratory Infection

Keywords

microbiota faringeo, infezioni respiratorie

Outcome Measures

Primary Outcomes (1)

• Evaluation of pharingeal microbiota

  Characterization of the pharyngeal microbiome (alpha and beta diversity, relative and differential abundances) in patients with symptoms attributable to respiratory infections

  24 months

Secondary Outcomes (1)

• Differences in microbiota in patients with diverse respiratory infections

  24 months

Study Arms (3)

controls

patients with S. pyogenes infection

patients with other respiratory infections

Eligibility Criteria

• Age: 0 Years - 20 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Patients who access the Pediatric Emergency Department with respiratory symptoms attributable to acute respiratory infection attributable to a bacterial and/or viral nature (diagnosed through nasopharyngeal swab as per normal clinical practice), who have given their informed consent to participate in this study. Subjects accessing the Pediatric Emergency Department who will perform a nasopharyngeal swab, as per normal clinical practice, with a negative result will also be included in the study as controls, considering the same exclusion criteria reported below. Informed consent will therefore be acquired upon entry to the Pediatric Emergency Department and in relation to the outcome of the nasopharyngeal swab the subjects will then be stratified into groups.

You may qualify if:

• age 0-20 years
• signs and/or symptoms of acute respiratory tract infection such as cold, pharyngitis, laryngitis, tracheitis, otitis, epiglottitis, laryngotracheitis, bronchitis and pneumonia.

You may not qualify if:

• antibiotic therapies in the last 30 days
• treatments with prebiotics or probiotics in the last 60 days (in particular containing Streptococcus salivarius)
• hormone therapies in the last 60 days
• local therapies in the last 60 days
• treatments with oral cavity disinfectants in the last 30 days
• presence of other pre-existing or ongoing respiratory pathologies
• current severe sepsis (sepsis criteria + organ dysfunction, peripheral hypoperfusion, hypotension)

Sponsors & Collaborators

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS: lead

MeSH Terms

Conditions

Respiratory Tract Infections

Condition Hierarchy (Ancestors)

Infections; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 30, 2024
• First Posted: August 16, 2024
• Study Start: September 15, 2024
• Primary Completion: August 15, 2025
• Study Completion (Estimated): August 15, 2026
• Last Updated: August 16, 2024

Record last verified: 2024-08